Imunon Croissance future

Future contrôle des critères 0/6

Les bénéfices de Imunon devraient diminuer de 22% par an tandis que son chiffre d'affaires annuel devrait croître de 87.4% par an. Le BPA devrait croître de en hausse de 34.7% par an.

Informations clés

-22.0%

Taux de croissance des bénéfices

34.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	87.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	26 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:IMNN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-37	-42	-41	4
12/31/2025	N/A	-27	-33	-36	4
12/31/2024	N/A	-20	-4	-29	4
9/30/2024	N/A	-19	-18	-18	N/A
6/30/2024	N/A	-18	-19	-19	N/A
3/31/2024	N/A	-19	-21	-21	N/A
12/31/2023	N/A	-20	-19	-19	N/A
9/30/2023	0	-28	-21	-20	N/A
6/30/2023	0	-31	-21	-20	N/A
3/31/2023	0	-31	-19	-19	N/A
12/31/2022	1	-36	-23	-23	N/A
9/30/2022	1	-27	-23	-23	N/A
6/30/2022	1	-26	-23	-22	N/A
3/31/2022	1	-26	-20	-19	N/A
12/31/2021	1	-21	-17	-16	N/A
9/30/2021	1	-20	-15	-15	N/A
6/30/2021	1	-22	-15	-15	N/A
3/31/2021	1	-22	-16	-15	N/A
12/31/2020	1	-21	-16	-16	N/A
9/30/2020	1	-22	-18	-18	N/A
6/30/2020	1	-19	-18	-18	N/A
3/31/2020	1	-20	-20	-20	N/A
12/31/2019	1	-17	-21	-20	N/A
9/30/2019	1	-8	-9	-9	N/A
6/30/2019	1	-7	-9	-8	N/A
3/31/2019	1	-10	-8	-8	N/A
12/31/2018	1	-12	-7	-7	N/A
9/30/2018	1	-22	-17	-17	N/A
6/30/2018	1	-23	N/A	-18	N/A
3/31/2018	1	-20	N/A	-18	N/A
12/31/2017	1	-21	N/A	-17	N/A
9/30/2017	1	-21	N/A	-17	N/A
6/30/2017	1	-22	N/A	-17	N/A
3/31/2017	1	-21	N/A	-17	N/A
12/31/2016	1	-22	N/A	-18	N/A
9/30/2016	1	-22	N/A	-18	N/A
6/30/2016	1	-20	N/A	-18	N/A
3/31/2016	1	-21	N/A	-20	N/A
12/31/2015	1	-22	N/A	-21	N/A
9/30/2015	1	-23	N/A	-23	N/A
6/30/2015	1	-26	N/A	-24	N/A
3/31/2015	1	-27	N/A	-22	N/A
12/31/2014	1	-25	N/A	-21	N/A
9/30/2014	1	-23	N/A	-18	N/A
6/30/2014	1	-20	N/A	-15	N/A
3/31/2014	1	-13	N/A	-16	N/A
12/31/2013	1	-13	N/A	-10	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: IMNN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: IMNN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: IMNN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: IMNN ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: IMNN ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de IMNN devrait être élevé dans 3 ans

Imunon Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 11% to US$9.75

Price target decreased by 17% to US$10.00

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Price target decreased to US$24.00

Price target decreased to US$32.67

Recent updates

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Market cap size

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?